menu
    • menu

    Company profile for LEBSA

    Lebsa-PSE
    News
    Talent and Transformation: Lebsa at Talent Day Barcelona 2025

    01 Oct 2025

    // PRESS RELEASE

    Solar Energy And Biorefinery Drive Sustainable Fine Chemicals

    21 Jul 2025

    // PRESS RELEASE

    LEBSA And Leitat Lead PHARO Pharma Water Regeneration Project

    25 Sep 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Lebsa RM

    Contact Supplier

    Website

    BPI Europe

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/OzK-q_3F3vg

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    LEBSA- Your strategic API source for niche molecules.

    Related CompaniesRelated Companies

    About

    Lebsa is an innovative European lab specializing in niche API synthesis, manufacture, and commercialization. With 70 years of experience, it is a reputable global player in generic API manufacturing. Based in Barcelona, Spain, Lebsa exports 90% of its production and operates advanced facilities. It has expertise in registering APIs across Europe, Canada, Taiwan, China, Russia, Brazil, and Japan. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LEBSASpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Ctra. de l'Hospitalet, 34 08940 Cornella, Barcelona
    Telephone
    Telephone
    +34 933770051
    Client Email
    Email
    lebsa@lebsa.com
    Client Website
    Website
    https://lebsa.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lebsa-api-manufacturer/
    youtube
    YouTube
    http://www.youtube.com/@lebsa-apimanufacturingcomp9525
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/lebsa-party-content-88244.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/lebsa-party-content-76467.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2021

    read-more

      https://www.pharmacompass.com/pdf/party/content/lebsa-party-content-1633923600.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 5773

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Talent and Transformation: Lebsa at Talent Day Barcelona 2025
    Talent and Transformation: Lebsa at Talent Day Barcelona 2025

    01 Oct 2025

    // PRESS RELEASE

    https://lebsa.com/blog/lebsa-at-talent-day-barcelona-2025/?_gl=1*rhttpd*_up*MQ..*_ga*MTk3NzAwNzk1MS4xNzY1MTgzNzY2*_ga_6PM2XWRJNJ*czE3NjUxODM3NjYkbzEkZzEkdDE3NjUxODQyMDMkajExJGwwJGgw

    PRESS RELEASE
    01 Oct 2025
    Share Share
    Solar Energy And Biorefinery Drive Sustainable Fine Chemicals
    Solar Energy And Biorefinery Drive Sustainable Fine Chemicals

    21 Jul 2025

    // PRESS RELEASE

    https://lebsa.com/blog/sustainable-innovation-in-fine-chemicals/?_gl=1*k5ap3r*_up*MQ..*_ga*MTc1MzMzNTU4MS4xNzU5NTc0MjMz*_ga_6PM2XWRJNJ*czE3NTk1NzQyMzIkbzEkZzEkdDE3NTk1NzQzNjUkajYwJGwwJGgw

    PRESS RELEASE
    21 Jul 2025
    Share Share
    LEBSA And Leitat Lead PHARO Pharma Water Regeneration Project
    LEBSA And Leitat Lead PHARO Pharma Water Regeneration Project

    25 Sep 2024

    // PRESS RELEASE

    https://lebsa.com/blog/lebsa-together-with-leitat-leads-the-pharo-project/

    PRESS RELEASE
    25 Sep 2024
    Share Share
    Lebsa Shareholders Meet: Tradition And Innovation To Drive Company Growth
    Lebsa Shareholders Meet: Tradition And Innovation To Drive Company Growth

    16 Nov 2023

    // PRESS RELEASE

    https://lebsa.com/blog/lebsa-shareholders-meeting/

    PRESS RELEASE
    16 Nov 2023
    Share Share
    Lebsa and Selectchemie Join Forces at CPHI Barcelona
    Lebsa and Selectchemie Join Forces at CPHI Barcelona

    31 Oct 2023

    // PRESS RELEASE

    https://lebsa.com/blog/lebsa-selectchemie-innovation-pharmaceutical/

    PRESS RELEASE
    31 Oct 2023
    Share Share
    Octenidine Dihydrochloride API: The Challenge for Lebsa in 2023
    Octenidine Dihydrochloride API: The Challenge for Lebsa in 2023

    19 May 2023

    // PRESS RELEASE

    https://lebsa.com/blog/octenidine-dihydrochloride-api-lebsa-challenge-2023/

    PRESS RELEASE
    19 May 2023
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    Inspections and registrations

    Check the inspections & registration from this company
    LEBSA

    ABOUT THIS PAGE

    Contact LEBSA and get a quotation

    LEBSA is a supplier offers 18 products (APIs, Excipients or Intermediates).

    Find Dequalinium Chloride bulk with CEP, JDMF offered by LEBSA

    Find Histamine Dihydrochloride bulk with CEP, JDMF offered by LEBSA

    Find Amisulpride bulk with CEP offered by LEBSA

    Find Betahistine Dihydrochloride bulk with CEP offered by LEBSA

    Find Betahistine Dimesilate bulk with CEP offered by LEBSA

    Find Mianserin Hydrochloride bulk with CEP offered by LEBSA

    Find Tiapride Hydrochloride bulk with CEP offered by LEBSA

    Find Betahistine Dihydrochloride bulk offered by LEBSA

    Find Bromopride bulk offered by LEBSA

    Find Dibrompropamidine Isetionate bulk offered by LEBSA

    Find Histamine Diphosphate Monohydrate bulk offered by LEBSA

    Find Lacidipine bulk offered by LEBSA

    Find Letermovir bulk offered by LEBSA

    Find Octenidine Hydrochloride bulk offered by LEBSA

    Find Picloxydine Dihydrochloride bulk offered by LEBSA

    Find Propamidine Isetionate bulk offered by LEBSA

    Find Sulpiride bulk offered by LEBSA

    Find Venetoclax bulk offered by LEBSA

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search